RE:RE:RE:RE:TIGIT class of checkpoint inhibitors fails with Keytruda
June 20, 2024 - Genentech CEO Alexander Hardy spoke to Endpoints News-
"We're in TIGIT, for example, and the latest count is 10 other companies developing TIGIT molecules, so we're going to be first, but the question is how long we're going to be best for. ...."
Since June 2024 a number of those Big Pharma companies referred to have dropped their TIGIT programs.
https://www.owler.com/reports/genentech--inc./q-a-with-genentech-ceo-alexander-hardy-on-medicare/1687292414725